ACUMEN PHARMACEUTICALS INC
ACUMEN PHARMACEUTICALS INC logo
ABOS

ACUMEN PHARMACEUTICALS INC (ABOS)

$5.753.2%

Market is closed
– opens on 8 PM, 06 Feb 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$5.65
Day's Range
$5.9799
$3.02
52-Week Range
$10.97
1 month return0.35%
3 month return11.27%
1 year return10.36%
5 year return69.58%

Analyst Recommendation

based on 12 analysts ratings

Buy
91%
Buy
8%
Hold
0%
Sell

Based on 12 Wall street analysts offering stock ratings for ACUMEN PHARMACEUTICALS INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 175.3%

Current

$5.75

Target

$15.83

Recommendation Trend

Based on 12 analyst

Current1M Ago3M Ago
Buy
11
3
11
Hold
1
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization243.1M
Book Value$4.86
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)1.55
PE Ratio3.83
Wall Street Target Price15.83

Valuation

Trailing PE3.83
Forward PE0.0
Price/Book (mrq)1.2
Enterprise Value35.7M
Enterprise Value/Revenue89.67
Enterprise Value/Ebitda-0.91

Technicals

50 Day MA5.72
200 Day MA5.52

Institutional Holdings

RA Capital Management, LLC

23.87%

Deep Track Capital, LP

9.23%

Sands Capital Ventures, LLC

8.35%

LAURION CAPITAL MANAGEMENT LP

2.95%

Great Point Partners LLC

2.93%

BlackRock Inc

2.72%

Company Information

Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.
OrganizationACUMEN PHARMACEUTICALS INC
Employees14
CEOMr. Daniel J. O'Connell M.B.A.
IndustryHealthcare

Discover more

Frequently Asked Questions

What is ACUMEN PHARMACEUTICALS INC share price today?

Can Indians buy ACUMEN PHARMACEUTICALS INC shares?

How can I buy ACUMEN PHARMACEUTICALS INC shares from India?

Can Fractional shares of ACUMEN PHARMACEUTICALS INC be purchased?

What are the documents required to start investing in ACUMEN PHARMACEUTICALS INC stocks?

What are today’s High and Low prices of ACUMEN PHARMACEUTICALS INC?

What are today’s traded volumes of ACUMEN PHARMACEUTICALS INC?

What is today’s market capitalisation of ACUMEN PHARMACEUTICALS INC?

What is the 52 Week High and Low Range of ACUMEN PHARMACEUTICALS INC?

How much percentage ACUMEN PHARMACEUTICALS INC is down from its 52 Week High?

How much percentage ACUMEN PHARMACEUTICALS INC is up from its 52 Week low?

What are the historical returns of ACUMEN PHARMACEUTICALS INC?

Who is the Chief Executive Officer (CEO) of ACUMEN PHARMACEUTICALS INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*